Mar 30, 2021Vfmcrp and Cara Therapeutics Announce European Medicines Agency Has Accepted to Review the Marketing Authorization Application for Difelikefalin
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the first therapy available in Europe...
Mar 26, 2021
St. Gallen, Switzerland, 26 March 2021 – Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6...
Mar 8, 2021Vifor Pharma and Cara Therapeutics Announce U.s. Fda Acceptance and Priority Review of Nda for Korsuva™* Injection in Hemodialysis Patients With Moderate-to-severe Pruritus
FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVATM injection would be first therapy for treatment of pr uritus in hemodialysis patients...
Mar 3, 2021
Vifor Pharma delivers strong full year results 2020 with an EBITDA of 576 million Swiss Francs representing over 29% growth1 Net sales up 3.7% at constant exchange rates (CER), despite significant...
Feb 2, 2021
Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieriand Gilbert Achermann will not stand for re-election St. Gallen, Switzerland, 02 February 2021